Drug Trial Radar · NCT05316428
A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects
Last checked: Nov 20, 2026Latest source record: May 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Feb 24, 2022
Primary completion
Apr 2, 2022
Study completion Apr 6, 2022
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 21 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is primarily to evaluate the effects of taking TPN171H tablets with alcohol on blood pressure, pulse,and pharmacokinetic in Chinese healthy male subjects.
Conditions
- Alcohol
- Phosphodiesterase Inhibitor
- Erectile Dysfunction
Interventions
TPN171H tablet plus alcoholDrug
10 mg TPN171H tablet QD plus 0.5 g/kg alcohol
alcoholOther
0.5 g/kg alcohol
TPN171H tabletDrug
10 mg TPN171H tablet QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum change in blood pressure (SBP and DBP)Time frame: 48 hours after treatment
- Maximum change in pulseTime frame: 48 hours after treatment
- The area under effect-time curve (AUEC0- 4h) of supine systolic (SBP) and diastolic (DBP) blood pressure, and pulseTime frame: 4 hours after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.